Kira M. Zack
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kira M. Zack has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anita K. McElroy
Division of Infectious Diseases, Department of Pediatrics, University of Pittsburgh
1 shared publication - Deborah Jacobs-Sera
Department of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
1 shared publication - Dominique J. Barbeau
Division of Infectious Diseases, Department of Pediatrics, University of Pittsburgh
1 shared publication - Graham F. Hatfull
Department of Biological Sciences, University of Pittsburgh
1 shared publication - John V. Williams
University of Pittsburgh School of Medicine
1 shared publication - Katherine S. Wetzel
Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA
1 shared publication
Latest Publications
- Open Access
- 23 November 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (12) , 2414
A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display
The explosion of SARS-CoV-2 infections in 2020 prompted a flurry of activity in vaccine development and exploration of various vaccine platforms, some well-established and some new. Phage-based vaccines were described previously, and we explored the possibility of using mycobacteriophages as a platform for displaying antigens of SARS-CoV-2 or other infectious agents. The potential advantages of using mycobacteriophages are that a large and diverse variety of them have been described and genomically characterized, engineering tools are available, and there is the capacity to display up to 700 antigen copies on a single particle approximately 100 nm in size. The phage body may itself be a good adjuvant, and the phages can be propagated easily, cheaply, and to high purity. Furthermore, the recent use of these phages therapeutically, including by intravenous administration, suggests an excellent safety profile, although efficacy can be restricted by neutralizing antibodies. We describe here the potent immunogenicity of mycobacteriophage Bxb1, and Bxb1 recombinants displaying SARS-CoV-2 Spike protein antigens.
- 23 November 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (12) , 2414
Open AccessA Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display
The explosion of SARS-CoV-2 infections in 2020 prompted a flurry of activity in vaccine development and exploration of various vaccine platforms, some well-established and some new. Phage-based vaccines were described previously, and we explored the possibility of using mycobacteriophages as a platform for displaying antigens of SARS-CoV-2 or other infectious agents. The potential advantages of using mycobacteriophages are that a large and diverse variety of them have been described and genomically characterized, engineering tools are available, and there is the capacity to display up to 700 antigen copies on a single particle approximately 100 nm in size. The phage body may itself be a good adjuvant, and the phages can be propagated easily, cheaply, and to high purity. Furthermore, the recent use of these phages therapeutically, including by intravenous administration, suggests an excellent safety profile, although efficacy can be restricted by neutralizing antibodies. We describe here the potent immunogenicity of mycobacteriophage Bxb1, and Bxb1 recombinants displaying SARS-CoV-2 Spike protein antigens.